China PD-1 clinical research boarded the cover of the willow knife

China PD-1 clinical research boarded the cover of the willow knife

January 7, 2019 Source: People's Daily Author: ZHAO Yong-new

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

A few days ago, a Chinese scientist's clinical study on the PD-1 anticancer drug, rituximab, was published in the form of a cover article in the first issue of "The Lancet and Hematology" in 2019. Stephen M. Ansell, editor-in-chief of the magazine, believes that ididilimumab provides an innovative and highly effective treatment model for cancer patients, improving patient accessibility.

The Lancet is the world's top medical journal, and its sub-published Blood Disease is a monthly magazine. It is very rare for Chinese scientific research to be published as a cover article for the magazine.

The author and first author of the article is Professor Shi Yuankai of the National Cancer Center. He led the clinical study of the domestic PD-1 inhibitor, salibizumab (commonly known as “Dabohu”). The results of the study showed that the objective response rate of the treatment of relapsed and refractory Hodgkin's lymphoma was 80.4%, and the side effects were small; its efficacy and safety were comparable to those of similar imported drugs.

Xindelibizon was officially approved by the State Drug Administration on December 24, 2018.

Face Recognition Time Attendance

Face Recognition Time Attendance,Free Software Face Recognition Time Attendance,Face Recognition Attendance Machine,Face Fingerprint Time Attendance

Shenzhen Bio Technology Co., Ltd , https://www.huifantech.com